Interim CEO Invests $50K in Open Market Purchase at Significant Premium

summarizeSummary

Hepion Pharmaceuticals' Interim CEO, Gary S. Stetz, purchased $50,000 worth of common stock at $0.04 per share, a substantial premium to the current market price of $0.0013, representing over 10% of the company's market cap.

check_boxKey Events

• Interim CEO Makes Significant Purchase

  Gary S. Stetz, Interim CEO and Director, acquired 1,250,000 shares of common stock for $50,000 in an open market transaction on April 21, 2026.

• Purchase at Substantial Premium

  The transaction was executed at $0.04 per share, which is significantly above the current market price of $0.0013.

• Substantial Investment Relative to Market Cap

  The $50,000 purchase represents approximately 10.5% of the company's current market capitalization.

• Transaction Linked to Recent Private Placement

  This purchase likely forms part of the $700,000 private placement at $0.04 per share, which was previously disclosed on April 22, 2026.

auto_awesomeAnalysis

This significant open market purchase by Interim CEO Gary S. Stetz demonstrates extremely strong conviction in Hepion Pharmaceuticals. On April 21, 2026, Mr. Stetz invested $50,000 to acquire 1,250,000 shares at $0.04 per share. This transaction, which appears to be part of the $700,000 private placement disclosed on April 22, 2026, represents over 10% of the company's market capitalization. The fact that the CEO purchased shares at $0.04, a price substantially higher than the current market price of $0.0013 (which is also near its 52-week high), indicates a strong belief in the company's long-term value despite recent market performance.